Its Go Time

My opinion - Dr. J hard at work with the Team. Madrigal has been very successful - stock chart indicates how successful. Good Management is a beautiful thing!!

From Cytodyn - CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to eventually use the results to pursue partnerships in the MASH space. Although CytoDyn will be primarily focused on oncology and inflammation in the coming months, we do believe that leronlimab could have a significant role in the treatment of MASH, whether as a standalone therapeutic or in a combination therapy approach.”

Our roll out begins. A study with LL with Resmetirom is genius by Madrigal. Outcomes are 2 - the combination of LL with Resmetirom is symbiotic and a win win for both companies or the combination of LL with Resmetirom is ineffective. Madrigal has protected its flank and enhances it forward motion with either outcome. Dr. J is vectored to crack the eggs of opportunity and this is the first under his leadership. Past efforts - Merck / LL / MD Anderson - has been quiet but NO indication that study was a failed mission. With this Resmetirom / LL combo there will begin discussions on other indications. LL will be in the news. LL will be discussed. LL becomes noticed because with Partnerships it lives and grows. Test / Verify - Test / Verify. Move the ball forward. As Dr J. states, our primary objectives are oncology and inflammation modulation. Remember, only a short time ago we weren't certain what were because we didn't completely understand the power of LL and its MOA. Not so today. Like Madrigal, we have an A Team Management group now. This joint venture is just the beginning and I for one am very excited for the company and the people we will help. Is Go Time. Standing by Tightlines.